G1 Therapeutics Halts Phase 3 Breast Cancer Drug Trial As Data Disappoints
G1 Therapeutics Halts Phase 3 Breast Cancer Drug Trial As Data Disappoints
g1 therapeutics因数据不理想而暂停第三期乳腺癌药物试验
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册